Antidote.me

Antidote Technologies is a digital health company based in London and New York City that operates a B2B patient recruitment platform connecting individuals with clinical trials. Led by CEO Laurent Schockmel, the organization provides data-driven search and matching technology to help pharmaceutical companies, biotechnology firms, and clinical research organizations accelerate their medical research programs. Operating with an estimated 50 to 100 employees, the enterprise generates revenue by charging trial sponsors for successfully enrolling diverse patient populations into their ongoing studies. The company has raised more than $35 million in total venture capital funding, including a $23.2 million financing round backed by institutional investors like LBO France, Merck Global Health Innovation Fund, Smedvig Capital, and Octopus Ventures. Originally launched as TrialReach before rebranding in 2016, the business was founded in 2011 by co-founders Pablo Graiver and Eyal Rabinovich.

High-Level Overview

Antidote.me (Antidote Technologies) is a digital health company that builds Antidote Match™, a clinical trial matching platform connecting patients to relevant trials by structuring global trial data into a machine-readable format. Patients answer simple questions to find matching studies, while researchers gain precision recruitment tools for faster enrollment.[1][3][8] It serves patients seeking treatment options, clinical trial sponsors like Pfizer and Eli Lilly, health systems, nonprofits, and over 250 patient communities reaching 15 million patients monthly, solving the core problem where 80-85% of trials delay or close due to participant shortages.[1][2][3]

The platform drives growth through partnerships with pharma giants, health tech firms like SEQSTER and PatientPoint, and nonprofits such as Breakthrough T1D and Beyond Type 1, emphasizing diversity, equity, and inclusion (DEI) in trials.[2][3][5][6] Antidote provides free search tech to advocacy groups while offering customized solutions to sponsors, reducing site burden and accelerating medical breakthroughs.[5]

Origin Story

Founded in 2010 in Noblesville, Indiana (with operations in the US and UK), Antidote launched as TrialReach before rebranding.[1][3] It emerged from the recognition that 85% of patients are unaware of trials and struggle to qualify, causing 80% of studies to delay—slowing medical progress.[1][3][8] Key leaders include CEO Laurent Schockmel, Co-CEO Samantha Veeck, and a team focused on high-tech, high-touch recruitment.[3][5]

Pivotal early traction came from pharma collaborations in 2015, where Pfizer, Eli Lilly, and Novartis selected Antidote to convert trial data into machine-readable formats, forming a consortium.[2] Over 12+ years, it built 300+ partnerships with nonprofits, bloggers, and tech firms, evolving from a search tool to a global recruiter powering trial awareness for millions.[2][3][5]

Core Differentiators

• Precision Matching Technology: Structures all trial data for instant, personalized matches via simple questionnaires, prescreening patients for high-quality referrals that cut researcher time and costs.[1][3][5][8]
• High-Tech, High-Touch Approach: Combines AI-driven search with human support, integrating real-time health data (e.g., via SEQSTER) for efficient, inclusive recruitment.[5]
• Vast Partnership Network: Collaborates with 300+ entities including pharma leaders (Pfizer, Novartis), 250+ patient portals, and point-of-care networks like PatientPoint's 7,300 US practices—unique scale for visibility and DEI (e.g., Spanish-language tools for diabetes trials).[2][3][5][6]
• Free Access for Patients/Nonprofits: No-cost tech for advocacy groups boosts participation; sponsors get optimized, trackable engagement, outperforming traditional methods.[2][5]

Role in the Broader Tech Landscape

Antidote rides the digital health and patient-centric research wave, addressing recruitment bottlenecks amid rising trial complexity and DEI mandates from regulators like the FDA.[4][6] Timing aligns with post-pandemic telehealth growth and AI data structuring, where 80% trial delays cost billions annually—Antidote's platform counters this by democratizing access.[1][3][8] Market forces like pharma's push for faster drug development (e.g., oncology, rare diseases) and nonprofit demands for inclusive trials favor its model.[2][6]

It influences the ecosystem by powering searches for millions, partnering with health systems and tech (e.g., PatientPoint integration at doctor visits), and enabling breakthroughs—e.g., Spanish tools for underrepresented diabetes patients—shifting trials from siloed to collaborative, global efforts.[3][5][6]

Quick Take & Future Outlook

Antidote is poised to expand its recruiter dominance through deeper AI integrations, more DEI-focused tools, and alliances like SEQSTER for real-time data, targeting even faster enrollments amid growing trial volumes.[5] Trends like personalized medicine, regulatory DEI requirements, and point-of-care tech will propel it, potentially scaling to billions in impact as trials digitize fully. Its influence may evolve into a standard infrastructure layer for research, bridging patients and cures more inclusively—reinforcing its core mission to end the participation crisis that stalls 80% of studies.[1][3][8]